Attiku, Yamini http://orcid.org/0000-0002-0229-8950
Nittala, Muneeswar Gupta http://orcid.org/0000-0002-3802-6594
Velaga, Swetha B. http://orcid.org/0000-0002-4637-6914
Ramachandra, Chaithanya
Bhat, Sandeep
Solanki, Kaushal
Jayadev, Chaitra http://orcid.org/0000-0001-8392-7159
Choudhry, Netan
Orr, Samantha Miyoko Ashlyn
Jiang, Shangjun
He, Ye
Sadda, SriniVas R.
Article History
Received: 23 July 2022
Revised: 20 December 2022
Accepted: 7 February 2023
First Online: 10 May 2023
Competing interests
: YA, MGN, SBV (None), CR: Eyenuk, Inc. (E), SB: Eyenuk, Inc. (E), KS: Eyenuk, Inc. (E), CJ (None), NC: Abbvie (C,S) Apellis ©, Bayer (C,S,R), Novartis (C), Bausch & Lomb (C), Alcon (C), Optos PLC (S,C,R), Topcon (S,C,R), Hoffman La Roche (C), SriniVas R Sadda: Amgen (C), Allergan (C), Genentech/Roche (C), Iveric (C), Oxurion (C), Novartis (C), Regeneron (C), Bayer (C), 4DMT (C), Centervue (C,R), Heidelberg (C,R), Optos (C,R), Merck (C), Apellis (C), Astellas (C), Carl Zeiss Meditec (R), Nidek (R), Topcon (R). The authors declare no competing interests.